|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 304, Issue 3, 1299-1306, March 2003
Department of Neurobiology Research, GlaxoSmithKline
Pharmaceuticals, Milan, Italy (M.G., P.F.Z., G.F., M.V., L.F., M.A.S.);
Neurology Centre of Excellence for Drug Discovery, New Frontiers
Science Park, Harlow, Essex, United Kingdom (M.G., P.F.Z., G.F., M.V.,
L.F., M.A.S.); and Department of Cell Biology and Physiology,
Washington University School of Medicine, St. Louis, Missouri (M.-H.R.,
K.J.B.)
We hypothesized that the up-regulated expression of one or more members
of the regulator of G protein signaling (RGS) family can cause an
attenuation of signaling via Gi/Go-coupled opioid receptors, and
thereby play a role in the development of hyperalgesia and accompanying
insensitivity to morphine observed in animal models of neuropathic
pain. Accordingly, we examined the mRNA expression of several RGS genes
in a rat model of chronic neuropathic pain induced by partial ligation
of the sciatic nerve. During the development of hyperalgesia, RGS4 was
the only isoform examined whose mRNA levels increased significantly (up
to 230%) in the lumbar spinal cord. In situ hybridization studies
confirmed that RGS4 is present in the dorsal horn of the spinal cord
where µ-opioid receptors (MORs) are also expressed. Overexpression of
RGS4 in human embryonic kidney 293 cells stably expressing
µ-opioid receptors predictably attenuated opioid agonist-induced
inhibition of adenylyl cyclase. This inhibitory effect was overcome
partially at high agonist concentrations, supporting the view that
morphine insensitivity is promoted by RGS4 overexpression. These
studies provide evidence that the up-regulation of RGS4 expression may
contribute to changes in pain signal processing that lead to the
development of hyperalgesia, and further affect its modulation by morphine.
This article has been cited by other articles:
![]() |
Q. Wang, L.-Y. Liu-Chen, and J. R. Traynor Differential Modulation of {micro}- and {delta}-Opioid Receptor Agonists by Endogenous RGS4 Protein in SH-SY5Y Cells J. Biol. Chem., July 3, 2009; 284(27): 18357 - 18367. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Penn and J. L. Benovic Regulation of Heterotrimeric G Protein Signaling in Airway Smooth Muscle Proceedings of the ATS, January 1, 2008; 5(1): 47 - 57. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Jaen and C. A. Doupnik RGS3 and RGS4 Differentially Associate with G Protein-coupled Receptor-Kir3 Channel Signaling Complexes Revealing Two Modes of RGS Modulation: PRECOUPLING AND COLLISION COUPLING J. Biol. Chem., November 10, 2006; 281(45): 34549 - 34560. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Grillet, A. Pattyn, C. Contet, B. L. Kieffer, C. Goridis, and J.-F. Brunet Generation and Characterization of Rgs4 Mutant Mice Mol. Cell. Biol., May 15, 2005; 25(10): 4221 - 4228. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-x. Xie and P. P. Palmer RGS Proteins: New Players in the Field of Opioid Signaling and Tolerance Mechanisms Anesth. Analg., April 1, 2005; 100(4): 1034 - 1042. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. F. Zaratin, G. Petrone, M. Sbacchi, M. Garnier, C. Fossati, P. Petrillo, S. Ronzoni, G. A. M. Giardina, and M. A. Scheideler J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 454 - 461. [Abstract] [Full Text] [PDF] |
||||